41 studies on Survodutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Polaris Peptides | 7 | 99.58% | View COA → |
| Uther Peptide | 7 | 99.27% | View COA → |
| Protide Health | 4 | 99.93% | View COA → |
| Felix Chemical Supply | 4 | 99.8% | View COA → |
| Peptide Sciences | 4 | 99.77% | View COA → |
| Qing Li Peptide | 4 | 99.04% | View COA → |
| Skye Peptides | 4 | 98.92% | View COA → |
| Anlv Biotechnology | 3 | 99.91% | View COA → |
Recent certificates: #32079 (99.81%) · #63189 (99.283%) · #50464 (99.93%) · #50465 (99.7%) · #50881 (99.96%) · #50882 (99.96%)
Manufacturers with published third-party certificates of analysis for Survodutide. Open a vendor to see every batch we've verified.
**Survodutide** represents a significant advancement in **obesity** pharmacotherapy, offering a dual `glucagon receptor`-`GLP-1 receptor` agonism that appears to deliver greater weight loss than current `GLP-1R` mono-…
The emergence of **survodutide** as a potential dual `GLP-1R`/`glucagon receptor` agonist could significantly expand the therapeutic landscape for **obesity** and **MASH**. For individuals struggling with these interc…
A plain language review clarifies **survodutide's** dual-agonist mechanism and promising clinical performance for **obesity** and **liver disease**.
This phase 3 data positions survodutide as a highly promising therapeutic option for individuals with **obesity** and **MASLD**, potentially offering a dual benefit by addressing both conditions simultaneously. **The …
This Phase 3 trial is critical for establishing the efficacy and safety of **survodutide** specifically for Japanese adults with obesity, a population often underrepresented in global trials. **The results will provid…
Establishing bioequivalence between different drug formulations is crucial for drug development. It ensures that any changes in formulation (e.g., for improved stability, manufacturing, or patient convenience) do not …
Optimizing Survodutide's formulation is critical for its future development as a potential treatment for obesity and NASH. A formulation with improved bioavailability could lead to more effective dosing strategies, po…
If the results demonstrate significant efficacy, survodutide could represent a transformative new therapeutic option for individuals struggling with the dual burden of overweight/obesity and Type 2 Diabetes. As a dual…
The successful outcome of this Phase III trial could represent a significant advancement in the treatment of overweight and obesity, particularly for the Chinese population, where specific therapeutic options are high…
If the results demonstrate significant efficacy and a favorable safety profile, Survodutide could represent a substantial advancement in the treatment landscape for obesity disease in Japan. This is particularly impor…
These Stage 1 results from the Daybreak trial provide compelling evidence for the efficacy of Setmelanotide as a targeted therapeutic option for patients with early-onset, severe obesity and hyperphagia driven by MC4R…
The successful completion of enrollment for this Phase III trial is a significant milestone in the development of new therapies for NASH and obesity. Given the limited treatment options for NASH, a condition affecting…
This Phase 1 study is crucial for the continued development of survodutide, as it provides foundational data on how the drug behaves in a specific ethnic population. Understanding the pharmacokinetics and safety profi…
If the results demonstrate significant and sustained weight loss, survodutide could represent a major advancement in the treatment of obesity and overweight, offering a new, potent therapeutic option. This is particul…
This paper primarily details the demographic and clinical characteristics of the study population at the start of the trial. The cohort comprised a diverse group of individuals with obesity, with an average age of 49.…
This comprehensive network meta-analysis provides compelling evidence that anti-diabetic agents are not only effective in managing diabetes but also hold significant promise for treating MASH, a condition with limited…
Survodutide's dual agonism represents a significant advancement, offering a multi-faceted approach to treating complex cardiometabolic diseases by simultaneously targeting weight loss, glycemic control, and hepatic st…
Understanding the baseline characteristics of participants in a large Phase 3 trial is crucial for interpreting the future efficacy and safety results, ensuring the findings are generalizable to the target patient pop…
This research boldly underscores the critical role of hepatic GCGR in mediating the profound metabolic benefits of dual GLP-1R/GCGR agonists like survodutide. Understanding this mechanism could lead to the development…
This research provides crucial insights into the central mechanism of action for Survodutide, demonstrating its direct engagement with brain regions critical for appetite regulation. Understanding that Survodutide act…
This research establishes selective amylin receptor agonism as a powerful new therapeutic strategy for metabolic diseases, potentially offering superior benefits over existing incretin-based therapies. The distinct me…
This blueprint provides a standardized, multi-faceted approach to evaluating the long-term efficacy of novel anti-obesity treatments like survodutide, moving beyond simple weight loss metrics. By focusing on disease m…
This proactive optimization of the SYNCHRONIZE™ Phase 3 program for survodutide is crucial for accelerating the development and availability of new obesity treatments. By identifying potential bottlenecks and effectiv…
This review underscores the significant therapeutic potential of survodutide as a novel treatment for both obesity and MASH, leveraging its unique dual GLP-1 and glucagon receptor agonism. Its ability to induce substa…
Optimizing drug formulation is crucial for enhancing patient convenience, adherence, and ultimately, therapeutic efficacy for conditions like obesity and MASH. If Formulation B2 demonstrates superior or comparable bio…
This Phase II trial provides compelling evidence that Survodutide could be a highly effective and much-needed therapeutic option for NASH and liver fibrosis, addressing a significant unmet medical need. The observed d…
Understanding the specific receptor binding profiles of BI 456906 is a critical first step in evaluating its potential as a novel therapeutic agent for obesity. If BI 456906 demonstrates significant and distinct gluca…
This Phase 1 study is critically important as it seeks to understand the fundamental metabolic mechanisms of survodutide, a novel therapeutic candidate for obesity. If survodutide demonstrates superior or distinct ben…
Establishing bioequivalence between different delivery devices for Survodutide is a critical step for its future clinical development and patient accessibility. If the pre-filled syringe and pen deliver the drug equiv…
If successful, this Phase 2 trial could represent a significant advancement in the treatment of chronic kidney disease, a condition with high morbidity and mortality. A drug that can effectively reduce albuminuria cou…
This large-scale Phase 3 trial is crucial for understanding the long-term cardiovascular impact of survodutide, a novel anti-obesity agent. A positive outcome would establish survodutide as a safe and effective treatm…
The successful outcome of this Phase III trial could represent a monumental step forward in treating MASH, a condition affecting millions globally with no current pharmacological cure. If Survodutide demonstrates sign…
As this is an active, not-yet-recruiting Phase 1 study (NCT07221591), specific results regarding the relative bioavailability of the two survodutide formulations are not yet available. The primary objective is to asse…
This study highlights Survodutide's potential as a groundbreaking treatment for obesity and MASH, leveraging a dual mechanism of action through GLP-1 and glucagon receptor agonism. Its ability to induce substantial we…
Free, no account — handy when you're working with Survodutide.